Across TCGA pan-cancer cohorts, ENTPD6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ENTPD6 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ENTPD6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ENTPD6 expression acts as an unfavorable survival marker.

STAD, UCEC, and LUSC are the cancer types where ENTPD6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	II,III,IV	0.169	0.641	.007	15	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	All	0.337	0.710	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ENTPD6 tumor-vs-normal RNA expression · all ENTPD6 data types